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DOI 10.1016/j.cmet.2011.08.013SUMMARY entiation and survival of early monocyte-osteoclast precursors isOsteoporosis is amultifactorial genetic disease char-
acterized by reduction of bone mass due to dysregu-
lation of osteoclast differentiation or maturation.
Herein, we identified a regulator of osteoclastogene-
sis, the murine homolog of inositol polyphosphate
4-phosphatase type IIa (Inpp4ba). Expression of
Inpp4ba is detected from early osteoclast differenti-
ation to activation stage. Targeted expression of
native Inpp4ba ex vivo repressed whereas phospha-
tase-inactive Inpp4ba stimulated osteoclast differ-
entiation. Inpp4ba acts on intracellular calcium level
that modulates NFATc1 nuclear translocation and
activation. In vivo mice deficient in Inpp4b displayed
increased osteoclast differentiation rate and poten-
tial resulting in decreased bone mass and osteopo-
rosis. Importantly, INPP4B in human was identified
as a susceptibility locus for osteoporosis. This study
defined Inpp4b as a major modulator of the osteo-
clast differentiation and as a gene linked to variability
of bone mineral density in mice and humans.
INTRODUCTION
Maintenance of bone mass is a dynamic process regulated by
two cellular mechanisms, bone formation and bone resorption.
While osteoblasts control bone formation, the osteoclasts are
responsible for bone matrix resorption: these functions are
tightly regulated via reciprocal crosstalk to maintain a constant
bone mass. Disruption of this strict balance leads to osteopo-
rosis or bone depletion and osteopetrosis or increase bone
mass, both of which are often linked to abnormal differentiation
or maturation of the osteoclast.
Osteoclasts are derived from hematopoietic precursors that
undergo multiple differentiation steps shared with the mono-
cyte-macrophage lineage (Boyle et al., 2003; Teitelbaum,
2000; Teitelbaum and Ross, 2003; Zaidi, 2007). Critical for differ-466 Cell Metabolism 14, 466–477, October 5, 2011 ª2011 Elsevier Inexpression of the M-CSF cytokine produced and secreted by
osteoblasts. Subsequently, themonocyte-osteoclast precursors
are differentiated by the RANK/RANKL (receptor activator of
NF-kB/ligand) signaling pathway into committed preosteoclasts
(Lacey et al., 1998) that migrate to the bone matrix where they
fuse to become mature multinucleated osteoclasts (Ishii et al.,
2009). Concomitantly, several intracellular signaling cascades
are triggered by RANKL/RANK. Two of these RANK cascades
implicate first recruitment of the TNF receptor associated factor
6 (TRAF6), leading to activation of two main differentiation effec-
tors, MAP kinases (p38, JNK, ERK) and NFkB. In another
cascade, RANK independently of TRAF6 can cooperate with
ITAMadaptors, FcRg andDAP12 linked to the immune receptors
OSCARandTREM2, to activatePLCg. PLCgactivationwill in turn
trigger the release of intracellular Ca2+ ERstores. Calciumvia cal-
cineurin phosphatase activitywill causeNFATc1 dephosphoryla-
tion and nuclear translocation (Koga et al., 2004) that will lead to
NFATc1 autoamplification and full activation (Asagiri et al., 2005).
NFATc1 like NFkB in the preosteoclast promote transcription of
a set of specific genes (calcitonin receptor, integrin beta3, and
tartrate resistant acid phosphatase), resulting in osteoclastmatu-
ration (Takayanagi et al., 2002; Takayanagi, 2005). TRAF6 in addi-
tion to a role in differentiation also promote cell survival signal
through activation of the phosphatidylinositol 3-phosphate
kinase (PI3kinase) and subsequently, the serine/threonine kinase
AKT/PKB (Wong et al., 1999). PI3kinase signaling can be antag-
onized by two known lipid phosphatases, Pten (phosphatase and
tensin homolog deleted on chromosome 10) and Ship1 (SH2-
containing inositol 5-phosphatase) that modulate the level of
PI3kinase second messengers (Carracedo and Pandolfi, 2008;
Golden and Insogna, 2004). Consistently, Pten overexpression
in RAW osteoclast-derived cells reduces the antiapoptotic func-
tion of Akt (Sugatani et al., 2003). In contrast, Ship1-null mice
display increased osteoclast proliferation and growth resulting
in decreased bone mass (Takeshita et al., 2002). While these
studies identified genes implicated in osteoclast survival, key
phosphatidyl inositol phosphate signaling regulators in osteo-
clast differentiation remain to be identified.
For characterization of molecular effectors involved in osteo-
clast differentiation/maturation and bone mass regulation,c.
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Figure 1. Regulation of Inpp4ba Expression in
Bone and Osteoclastogenesis
(A) Semiquantitative expression of Inpp4ba in total bone
from the gl osteopetrotic mice (gl/gl) was analyzed in
comparison to wild-type mice (+/+). Expression of Runx2
and Ship1 served as osteoblast and osteoclast markers,
respectively, and b-actin as internal control. RT, reverse
transcriptase.
(B) Semiquantitative expression analysis of Inpp4ba in
osteoclasts from the gl osteopetrotic mice (gl/gl) relative to
wild-type mice (+/+) was performed using Ship1 and
b-actin as controls. RT, reverse transcriptase.
(C) Quantitative real time PCR of Inpp4ba in total bone and
osteoclasts from wild-type (+/+; n = 3) and osteopetrotic
(gl/gl; n = 3) mice relative to the ribosomal protein S16
control. Data are arbitrary units presented as mean ±
standard deviation (***p < 0.001).
(D) Semiquantitative expression of Inpp4ba in total bone
from the c-src/ osteopetrotic mouse was analyzed
compared to wild-type (+/+) controls and b-actin as
internal control.
(E) Semiquantitative expression of Inpp4ba and b isoforms
was analyzed in wild-type total bone, primary osteoblasts
(OBs), and osteoclasts (OCs). Only Inpp4ba isoform was
detected in both total bone and OCs but not in OBs.
Expression of Runx2 and Ship1 served as osteoblast and
osteoclast markers, respectively, and b-actin as control.
RT, reverse transcriptase.
(F) Inpp4ba expression pattern throughout ex vivo osteo-
clast lineage differentiation was determined using the
preosteoclast/osteoclast Acp5 marker gene and b-actin
as controls.
See also Figure S1.
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Inpp4b Modulates Bone Massbone gene expression profiles from an osteopetrotic mouse
mutant were performed and identified the inositol polyphosphate
4-phosphatase type IIa (Inpp4ba), a member of the PI3kinase
signaling pathway markedly downregulated. We demonstrated
by ex vivo and in vivo analysis that Inpp4b is a phosphatase-
dependent repressor of osteoclast differentiation. Mice deficient
for Inpp4b displayed bone loss and osteoporosis. Inpp4b intra-
cellular mechanism acts by controlling calcium signaling and
the NFATc1 osteoclast differentiation pathway. The importance
of Inpp4b in human was revealed through genetic analysis, as
a novel determinant of bone mineral density or osteoporosis
susceptibility locus in premenopausal women.
RESULTS
Downregulation of Inpp4ba in Bone Resorption Defect
To identify critical determinants of osteoclast differentiation,
bone expression profiles from the osteopetrotic gl/gl homozy-
gous mice with enhanced osteoclast differentiation and matura-
tion (Rajapurohitam et al., 2001) were compared to wild-type
control mice. One of the identified transcripts, downregulated
by 80% in quantitative PCR from gl/gl bone tissue, encodes
the murine homolog of the rat inositol phosphatase Inpp4ba
(Ferron and Vacher, 2006). Inpp4ba expression in gl/gl total
bone tissue or osteoclasts, showed significant downregulation
of the transcript relative to wild-type controls in semiquantitative
and real-time PCR analysis (Figures 1A–1C). This downregula-
tion appears specific to the gl/gl phenotype, as expression ofCellShip1 inositol phosphatase with a known role in murine bone
homeostasis (Takeshita et al., 2002), was unaffected in gl/gl
tissues (Figures 1A and 1B). In addition, expression of Inpp4ba
was unchanged in bone of the c-src and oc/oc null osteopetrotic
mutants (Figure 1D and Figure S1 available online). These results
suggested that downregulation of Inpp4ba is not secondary to
osteopetrosis or associated with a general alteration in the regu-
lators of PtdInsP second messengers.
Differential Expression of the Inpp4ba Isoform
in Osteoclasts
Because the mouse Inpp4b gene encodes two isoforms (a and
b), the expression of each isoform was evaluated. Analysis of
Inpp4ba expression from wild-type bone tissues, containing
both osteoclast (OC) and the bone-forming osteoblast (OB) cells,
demonstrated that only the Inpp4ba isoform is expressed in vivo
in association with expression of Ship1 an inositol phosphatase
expressed in the monocyte-macrophage/osteoclast lineage and
of Runx2 a transcription factor specific of the osteoblast lineage
(Figure 1E). Analysis of the two bone cell subpopulations isolated
separately from primary cell cultures showed high levels of
Inpp4ba expression in OCs compared to very low to undetect-
able level in OBs. Interestingly, Inpp4ba expression showed
a progressive increase during OC differentiation that paralleled
expression of the specific marker gene tartrate resistant acid
phosphatase Acp5 (Figure 1F), suggesting that Inpp4ba could
play a prime role in the regulation of osteoclast lineage differen-
tiation to maturation.Metabolism 14, 466–477, October 5, 2011 ª2011 Elsevier Inc. 467
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Differentiation
To determine the role of Inpp4ba and the involvement of phos-
phatase activity in the osteoclast lineage differentiation/matura-
tion, we used the monocytic RAW 264.7 cell line. Differentiation
potential and kinetics in presence of RANKL were analyzed from
three experiments with two stable clones expressing the native
Inpp4ba-EGFP, a phosphatase inactive Inpp4ba(C845A)-EGFP
mutant protein or the EGFP control (Figure S2). The number and
size of fully differentiated/mature osteoclasts from the different
transfected clones was markedly reduced by expression of
active Inpp4ba-EGFP compared to inactive Inpp4ba
(C845A)-EGFP and control EGFP clones at day 5 (Figures 2A
and 2D). The number of differentiated/mature OCs produced
from Inpp4ba-EGFP clones was decreased by 5-fold relative
to controls and by 10-fold relative to inactive Inpp4ba (Fig-
ure 2B). Further, expression of mutant Inpp4ba(C845A)-EGFP
caused earlier occurrence of multinucleated tartrate-resistant
acid phosphatase (TRAP)-positive OCs at day 3 in comparison
to controls whereas only mononucleated cells were detected at
that stage with active Inpp4ba-EGFP (Figures 2A and 2B). Since
cell density can affect OC differentiation potential, parallel
kinetics of differentiation for the transfected clones were carried
out using a range of plated cells. As shown in Figure 2C,
Inpp4ba (C845A)-EGFP clones exhibited at low cell densities
not only increased cell differentiation rate but also a 3-fold
higher differentiation cell potential in comparison with EGFP
and even higher with Inpp4ba-EGFP clones. Associated with
a slower OC differentiation rate in Inpp4ba-EGFP clones, OC
size was also significantly decreased relative to control cells
(Figures 2A and 2D). Accordingly, 65% of cells from
Inpp4ba-EGFP clones had three to four nuclei per OC, whereas
60% of cells from control and 70% of cells from mutant
Inpp4ba had at least five nuclei per osteoclast (Figure 2E).
Consistently, resorption activity of Inpp4ba-EGFP was
decreased relative to mutant Inpp4ba(C845A)-EGFP clones
and to controls by 5- and 3-fold, respectively (Figure 2F).
Concurrent to Inpp4ba-EGFP effect on osteoclastogenesis, In-
pp4ba-EGFP expression also caused increase apoptosis in
comparison to mutant Inpp4ba and controls (Figure 2G). These
data suggested that the phosphatase function in Inpp4ba
modulates not only cell size but also the rate and potential of
osteoclast differentiation.
Inpp4ba as a Modulator of NFATc1 in Osteoclast
Differentiation
To gain insight into the second messengers critical for cellular
signaling modulation by Inpp4b, we first identified Inpp4b
native substrate(s) preference through an in vitro hydrolysis
assay. As shown in Figure 3A, Inpp4b can dephosphorylate
PI(3,4)P2 as previously reported (Norris et al., 1997), whereas
the inactive Inpp4ba(C845A) was incapable of hydrolyzing
PI(3,4)P2. Inpp4b was equally efficient (20%) at hydrolyzing
the native substrate PI(4,5)P2 but was unable to hydrolyse
PI(3,4,5)P3 and Ins(1,4,5)P3. The low efficiency in hydrolysing
phosphatidylinositol (PIPs) by Inpp4b is consistent with mild
or unaffected PIPs levels in the clones (Figures S2D and
S2E). Strikingly, Inpp4b preferred substrate for dephosphoryla-
tion was Ins(1,3,4)P3 with 5-fold higher efficiency (95%)468 Cell Metabolism 14, 466–477, October 5, 2011 ª2011 Elsevier Inthan PI(3,4)P2 or PI(4,5)P2 (Figure 3A). In all cases, none of
the potential substrates were hydrolyzed by the mutant
Inpp4ba(C845A), showing that this mutation abrogate Inpp4b
phosphatase enzymatic activity.
To directly determine the intracellular signaling cascade(s)
modulated by Inpp4ba upon RANKL activation, we investigated
the major signaling effectors implicated in osteoclast survival
(PI3K/AKT) and differentiation (MAPK, PLCg). In absence of
serum, we observed no AKT activation (t = 0) in stable clones ex-
pressing Inpp4ba-EGFP, Inpp4ba(C845A)-EGFP, or EGFP, but
upon addition of RANKL, all clones showed a similar mild
increase in AKT phosphorylation (Figure S3A). In presence of
serum, P-AKT level appear activated even prior RANKL addition
in Inpp4ba(C845A)-EGFP or EGFP clones but remained low in
clones expressing Inpp4ba-EGFP, an observation which may
account for the increased apoptosis in these cells (Figure S3B
and Figure 2G). The MAP kinases p38, ERK, and JNK phosphor-
ylation levels were then monitored independently of serum stim-
ulation and were not significantly altered in the stable clones
expressing Inpp4ba-EGFP, Inpp4ba(C845A)-EGFP, or EGFP
(Figure S3A). Similarly, no changes in kinetic pattern of activation
or in expression levels were detected for these effectors. Since
PI(4,5)P2 was mildly hydrolyzed by Inpp4b in vitro, we also
analyzed in the three stable clones P-PLCg (1 and 2) levels rela-
tive to total PLCg. However, active or mutant Inpp4b did not alter
PLCg phosphorylation and kinetic patterns in presence or not of
RANKL compare to controls (Figures S3C and S3D). These data
suggest that Inpp4ba does not modulate osteoclast differentia-
tion via the PI3K/AKT, MAPK, or PLCg pathways.
To examine whether the transcription factors NFkB p50 and
NFATc1 were activated by Inpp4ba, total cellular and nuclear
expression levels were analyzed after RANKL stimulation.
NFkBp50 nuclear level appeared slightly repressed by the active
Inpp4ba (Figure 3B). Reciprocally, a sustained but mild increase
of nuclear NFkB p50 level independently of RANKL stimulation
was detected with the inactive Inpp4ba that may affect OC
gene targets (Figure 3B). Concomitantly, expression of active
Inpp4ba caused a decrease in NFATc1 nuclear levels whereas
total cellular levels of NFATc1 were not reduced (Figure 3B and
Figure S3E). In contrast, expression of the inactive Inpp4ba
(C845A) resulted in constitutively and markedly elevated nuclear
and cytosolic NFATc1 levels compared to controls well above
the increase in total cellular NFATc1 (Figure 3B and Figures
S3E andS3F). Quantification of NFATc1 nuclear to cytosolic ratio
indicates that expression of the phosphatase inactive Inpp4ba
induced a strong nuclear translocation compared to control
and active Inpp4ba (Figure S3F). These data suggest an impor-
tant role for Inpp4ba in regulation of NFATc1 localization that is
dependent on phosphatase activity.
Since RANKL signaling activates intracellular calcium levels
that promote NFATc1 nuclear translocation (Crabtree andOlson,
2002), we investigated whether Inpp4ba could be amodulator of
intracellular calcium by measuring Ca2+ oscillations in the three
different RAW clones. In all three experiments, the control clones
showed Ca2+ oscillations in 45% of cells from 24 to 48 hr after
RANKL stimulation, (Figure 3C). With expression of active
Inpp4ba, the percentage of Ca2+ oscillating cells was signifi-
cantly decreased relative to controls, correlating with reduced
NFATc1 nuclear levels. Inversely, the number of Ca2+ oscillatingc.
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Figure 2. Inpp4ba Impairs Osteoclastogenesis in RAW Cells
(A) Comparison of RAW cell differentiation kinetic into osteoclasts transfected with control (EGFP), native Inpp4ba (Inpp4ba-EGFP), and phosphatase-inactive
Inpp4ba (Inpp4ba-C845A-EGFP) monitored upon RANKL stimulation (50 ng/ml) for 2–5 days and detected by TRAP staining.
(B) Quantification of mature osteoclast number at various differentiation stages for the three RAW transfected clones (n = 4 each) as in (A). Values are mean ±
standard error of the mean (SEM; ***p < 0.001).
(C) Comparison of RAW cell differentiation kinetic with various seeded cell numbers from the three RAW transfected clones as in (A). TRAP signal corresponding
to OC appearance was quantified from 2–5 days after RANKL stimulation with Image Quant software.
(D) Quantification of osteoclast size at various differentiation stages for the three RAW transfected clones (n = 2 each) as in (A). Data are presented as mean cell
surface area ± SEM; statistical comparison of OC size was performed between control and active or inactive Inpp4ba differentiation groups (**p < 0.01).
(E) Quantification of the number of nuclei in individual osteoclast (subgroups of 3 to >20) at day 5 of differentiation for the three RAW transfected clones upon
RANKL stimulation (50 ng/ml).
(F) OC resorption activity was quantified by assay of pit area from osteoclast derived of the three RAW transfected clones seeded onOsteologic substrate. Values
are mean ± SEM (*p < 0.05; **p < 0.01).
(G) Quantification of apoptosis in preosteoclast derived from the three RAW transfected clones stained for AnnexinV and analyzed by FACS. Values are mean ±
SEM (**p < 0.01; ***p < 0.001).
See also Figure S2.
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Figure 3. Inpp4ba Modulates the NFATc1 Signaling Pathway during Osteoclastogenesis
(A) Analysis of Inpp4b substrate specificity was carried out on native substrates in a malachite assay using equivalent immunoprecipitates from cell extracts of
control EGFP, native Inpp4ba-EGFP, and phosphatase-inactive Inpp4ba-C845A-EGFP. This assay showed that the C845 residue is critical for Inpp4b pho-
phatase activity. Values are mean ± SEM (****p < 0.0001).
(B) Comparison of nuclear and cytosolic NFATc1 andNFkBp50 levels in the three RAW transfected cells (control EGFP, native Inpp4ba-EGFP, and phosphatase-
inactive Inpp4ba-C845A-EGFP) at different time points (0–60 min) upon RANKL (100 ng/ml) stimulation, relative to b-actin and tubulin as controls.
(C) Analysis of Ca2+ oscillations performed on RAW transfected cells (control EGFP, native Inpp4ba-EGFP, and phosphatase-inactive Inpp4ba-C845A-EGFP)
after 48 hr of RANKL treatment (preosteoclasts). Maximum fluorescence ratio was obtained by addition of 10 mM ionomycin at the end of tracings (arrow). Data
are presented as mean of percentage oscillating cells ± SEM (*p < 0.02).
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Figure 4. Ablation of Inpp4b in Mice Causes
Decreased Bone Mass
(A) Undecalcified sections of femur (top) and
vertebra (bottom) from control and Inpp4b/mice
(8 weeks old) were stained with Von Kossa.
(B) Femur sections of control and Inpp4b/ mice
were monitored for trabecular bone structure,
osteoclast size and number by TRAP staining.
(C) Osteoclast number and size in Inpp4b/ mice
(n = 6) were compared to controls (n = 6). Data are
presented as mean ± SEM (**p < 0.01; ***p <
0.001).
(D) Bone resorption was evaluated by excretion of
urinary deoxypyridinoline (DPD) crosslinks in
Inpp4b/ mice compared to controls (n = 11
each). Values are mean ± SEM (*p < 0.05).
(E) In vivo osteoblast number (OB number/bone
perimeter) was quantified after bone staining with
alkaline phosphatase (**p < 0.01). Osteoblast
activity was monitored by mineralization apposi-
tion rate (MAR). Quantification was carried out
following calcein double labeling in Inpp4b/
mice relative to control. Values are mean ± SEM
(*p < 0.05).
(F) Microcomputed tomography analysis of male
femur from control and Inpp4b/ mice (8 weeks
old) was carried out to quantify relative bone
volume (BV/TV), trabecular numbers, trabecular
spacing, and erod surface/bone surface (ES/BS).
Values are mean ± SEM (*p < 0.05; ***p < 0.001).
(G) Histomorphometrical analysis of male verte-
brae from control and Inpp4b/ mice (8 weeks
old) quantify relative bone volume (BV/TV) and
bone mineral density (BMD). Values are mean ±
SEM (*p < 0.05; **p < 0.01).
See also Figure S4 and Table S1.
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increased compared to control (Figure 3C). These analyses indi-
cate that Inpp4ba can modulate Ca2+ signaling that can then
regulate NFATc1 pathway.
Because active Inpp4ba have a negative effect on NFATc1
nuclear levels and presumably translocation, we quantified
expression of NFATc1 known downstream osteoclast-specific
target genes (Asagiri et al., 2005;Matsumoto et al., 2004; Takaya-
nagi et al., 2002) during OC differentiation in the three different
transfected clones (Figure 3D). In control cells, Nfatc1, Acp5,
cathepsin K (Ctsk), and b3 integrin (Itgb3) expression gradually
increased from 0 to 72 hr. In contrast, Nfatc1, Acp5, Ctsk, and
Itgb3 transcriptional levels in cells expressing active Inpp4ba(D) Comparison of quantitative expression kinetics for NFATc1 target genes (Acp5, Itgb3, Ctsk, Nfatc1) dur
EGFP, native Inpp4ba-EGFP, and phosphatase-inactive Inpp4ba-C845A-EGFP) clones (n = 2 each) upon RAN
**p < 0.01; ***p < 0.001).
See also Figure S3.
Cell Metabolism 14, 466–477were markedly decreased by 2- to 4-fold
throughout the 72 hr treatment relative
to the control (Figure 3D), consistent with
the reduced NFATc1 nuclear levels. In
the cells expressing the inactive In-
pp4ba(C845A) levels of the target genesAcp5,Ctsk, and Itgb3were elevated during differentiation corre-
lating with increase NFATc1 translocation and autoamplification.
These results showed that Inpp4ba is a major determinant of
NFATc1 nuclear translocation and transcriptional activation.
Inpp4b Regulates Bone Mass In Vivo
To determine whether Inpp4b regulates bone remodeling in vivo,
mice deficient in Inpp4bwere generated and adult mice obtained
at the expected mendelian ratio with loss of Inpp4b protein in
osteoclasts (Figure S4). Analysis of 8 weeks old Inpp4b/
male mice showed a decrease in femur trabecular bone density
(Figure 4A) associated with a 2- to 3-fold increase in TRAP+ oste-
oclast number and size compared to controls (Figures 4B anding differentiation of the RAW transfected (control
KL stimulation. Values are mean ± SEM (*p < 0.05;
, October 5, 2011 ª2011 Elsevier Inc. 471
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Figure 5. Inpp4b Modulates Osteoclast Differentiation Ex Vivo
(A) Ex vivo osteoclast differentiation kinetic from Inpp4b/ bone marrow
monocytes relative to control was monitored upon M-CSF (10 ng/ml) and
RANKL (50 ng/ml) stimulation for 7 days and detected by TRAP staining.
(B) Quantification of osteoclast size ex vivo at various differentiation stages for
Inpp4b/ (n = 3) and controls (n = 3). Data are mean ± SEM, and statistical
comparison of OC size was performed between control and null Inpp4b
differentiation groups (***p < 0.001).
(C) Quantification of bone resorption was performed from Inpp4b/ and
control osteoclasts on dentine substrate and pit resorption area quantified by
toluidine blue staining. Values are mean ± SEM (**p < 0.01).
See also Figure S5.
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Inpp4b Modulates Bone Mass4C). Accordingly, bone resorption, as determined by urinary de-
oxypyridinoline (DPD) crosslinks excretion, was significantly
increased in adult Inpp4b/ mice in comparison to control
mice (Figure 4D). Because elevated bone resorption is coupled
to bone formation (Martin and Sims, 2005), we examined bone
formation in the Inpp4b/ mice. Importantly, our analysis
showed enhanced osteoblast cell population in Inpp4b/
mice compared to controls resulting in a significant increase in
the mineral apposition rate (MAR) in vivo and mineralization
potential ex vivo (Figure 4E and Figures S4K and S4L). Since
we did not detected Inpp4b expression in osteoblasts (Fig-
ure 1E), this result indicated that Inpp4b does not impede the
osteoclast/osteoblast coupling mechanism as revealed by the
BFR (Figure S4F). We then investigated whether loss of Inpp4b
could have an impact on long bones growth and detected small472 Cell Metabolism 14, 466–477, October 5, 2011 ª2011 Elsevier Inbut consistent bone length decrease in Inpp4b/ compared to
controls (Figure S4J). Further characterization of the bone
phenotype of Inpp4b/ mice showed from microCT and histo-
morphometry analyses of the femur at 8 weeks and 4 months
of age, a major decrease in bone volume fraction (BV/TV) (Fig-
ure 4F, Figures S4G–S4I, and Table S1). Interestingly, in young
8-week-old animals, this decreased bone mass is associated
with important reduction in trabeculae number whereas in
4-month-old mice it was correlated with major decrease in
trabecular thickness (Table S1); such a difference is most likely
due to intense bone structure remodeling in young animals
(Beamer et al., 1996). In addition, histomorphometric quantifica-
tion of bone volume fraction in vertebra, acknowledged as
a complementary and highly reliablemethod for bonemass anal-
ysis (Ducy et al., 2000b), also revealed 25% reduction in
Inpp4b/ bone volume relative to controls (Figure 4G). Hence,
Inpp4b/ mice display net bone loss, reduced bone growth
andosteoporosis. These data revealed that Inpp4ba is a negative
modulator of osteoclast differentiation with a major physiologic
impact on bone mass.
Inpp4b Modulates Osteoclast Differentiation through
NFATc1 Signaling
To assess the differentiation potential of Inpp4b/ pre-osteo-
clasts ex vivo, osteoclasts were derived from bone marrow cell
cultures. A significant 1.7-fold increase in OC production in
Inpp4b/ culture (232 ± 39; n = 8) compared to controls
(137 ± 23; n = 8) was measured (Figure 5A) that correlated with
the increased number of TRAP+ cells in vivo (Figures 4B and
4C). OC size was also increased by 3-fold in Inpp4b/ culture
(Figure 5B) and as illustrated in Figure 5A. Moreover, the kinetic
of OC differentiation from Inpp4b/ bone marrow cells was
significantly accelerated compared to controls (Figure 5B). Anal-
ysis and quantification of Inpp4b/ osteoclast activity demon-
strated significant increase in pit area formation by 50% rela-
tive to controls (Figure 5C). This increased resorption is likely
due to the expanded osteoclast cell population (Figure 4C and
Figure S4H), and not to increase in individual osteoclast activity
(Figure 5C). Together, these results confirmed that Inpp4b is
a negative modulator of osteoclast differentiation.
Since Inpp4b-deficient preosteoclasts showed increase
differentiation potential, main lipid phosphatases and down-
stream RANKL signaling effectors were analyzed. Expression
of the lipid phosphatase Pten and Ship1 was unaffected in
Inpp4b/ osteoclasts, indicating no indirect impact of Inpp4b
on PI3K signaling (Figure S6A). As observed in RAW-transfected
cells, RANKL-induced Ca2+ oscillation in Inpp4b/ preosteo-
clasts was increased by 28% relative to controls (Figure 6A).
Consequently, NFATc1 nuclear levels were significantly elevated
in Inpp4b/ cells as determined by nuclear to cytosolic ratio
relative to controls (Figure 6B and Figure S6B and S6C), whereas
activation of AKT, ERK, and p38 after stimulation was similar in
pre- and mature Inpp4b/ osteoclasts when compared to
controls (Figure S5). Consistently, NFATc1 transcriptional target
genes, Nfatc1, Acp5, Ctsk, Itgb3, Itgav, and Ctr showed a signif-
icant increase and similar induction kinetic of expression in
Inpp4b/ cells (Figure 6C). These results indicate that Inpp4b
acts as a negative regulator of osteoclast differentiation down-
stream of RANK/RANKL signaling via NFATc1.c.
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Figure 6. Inpp4b Modulates Osteoclast Differenti-
ation through NFATc1
(A) Analysis of Ca2+ oscillations performed on the control
and Inpp4b/ preosteoclasts after 24 hr of RANKL
treatment. Maximum fluorescence ratio was obtained by
addition of 10mM ionomycin at the end of tracings (arrow).
Data are presented as mean of percentage oscillating
cells ± SEM (*p < 0.05).
(B) Nuclear NFATc1 levels in Inpp4b/ and in control
bone marrow monocytes derived osteoclasts was evalu-
ated by immunoblot upon stimulation with RANKL (100 ng/
ml) for various times (0–30min). Lamin C served as internal
nuclear control.
(C) Comparison of quantitative expression kinetics for
NFATc1 target genes (Acp5, Itgb3,Ctsk,Nfatc1, Itgav,Ctr)
during osteoclast lineage differentiation of Inpp4b/ and
control. Data are presented as mean ± SEM; statistical
comparison was performed between control and null
Inpp4ba differentiation groups (*p < 0.05; **p < 0.01; ***p <
0.001).
See also Figure S6.
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Density Variability
Considering that Inpp4b modulates bone mass in mice and that
INPP4B maps to chromosome 4q (Ferron and Vacher, 2006),
where quantitative trait loci for bone mineral density (BMD)
have been localized (Deng et al., 2002; Ralston et al., 2005),
we hypothesized that INPP4B could be a candidate gene for
association with this trait in humans. Screening of the Utah resi-
dents with ancestry from northern and western Europe popula-
tion from HapMap detected 493 single nucleotide polymor-
phisms (SNPs) within the INPP4B genomic locus. Eighty-three
Tag SNPs were analyzed for an association with femoral
neck bone mineral density (FN BMD) or lumbar spine BMD
(LS BMD) in a Quebec premenopausal women sample (n =
677) (Giroux et al., 2007). Three SNPs, rs2627804, rs13104269,Cell Metabolism 14, 4and rs2636683, were significantly associated
with BMD variability (p value < 0.05). We then
tested these three SNPs for replication in
a second sample of premenopausal women
(Toronto, n = 660). Since both the Quebec and
Toronto samples were established on the
same physiologic characteristics, genotyping
results from both samples were combined to
increase the number of individuals and statis-
tical power. The three SNPs remained associ-
ated in the combined samples with a lower p
value, indicating that the gene effect was in
the same direction (Table 1). For the SNP
rs2627804, the genotypes GG and GA were
associated with similar mean BMD in both FN
and LS, whereas the AA genotype was signifi-
cantly associated with higher mean BMD for
these sites. Rs2636683, which was in high
linkage disequilibrium with rs2627804 and
strongly correlated with it (r = 0.61), was also
associated with FN but to a lesser extent.Rs13104269 showed a weak association with LS BMD and
a trend with FN.
DISCUSSION
Characterization of molecular regulators is critical to dissect
signaling pathways that control osteoclastogenesis and modu-
late bone remodeling, in both normal and pathologic conditions.
Herein, our study identified a modulator of osteoclast differenti-
ation, Inpp4ba, via its phosphatase function. In vivo ablation of
Inpp4b showed that the primary function of Inpp4ba is to repress
osteoclastogenesis. Inpp4ba regulation acts specifically on
intracellular calcium to inhibit NFATc1 nuclear localization and
transcription of osteoclast-specific target genes. Importantly,
in humans INPP4B is associated with bone mineral density66–477, October 5, 2011 ª2011 Elsevier Inc. 473
Table 1. Analysis of INPP4B Variants in Quebec and Toronto Premenopausal Samples
Frequencies
LS BMD Meansa
(g/cm2)
95% Confidence
Interval p Value
FN BMD
Meansa (g/cm2)
95% Confidence
Interval p Value
Quebec Premenopausal Sample
rs13104269 AA = 578,
AG/GG = 102
1.175, 1.145 1.162–1.188,
1.118–1.172
0.036 0.915, 0.892 0.904–0.926,
0.868–0.916
0.071
rs2627804 GG = 188,
GA = 340,
AA = 164
1.161, 1.169,
1.187
1.141–1.181,
1.154–1.185,
1.166–1.209
0.167 0.902, 0.907,
0.939
0.885–0.920,
0.893–0.920,
0.920–0.958
0.005
rs2636683 CC = 313,
CT = 298,
TT = 65
1.177, 1.168,
1.152
1.161–1.194,
1.151–1.184,
1.118–1.185
0.344 0.924, 0.904,
0.888
0.909–0.938,
0.890–0.919,
0.859–0.917
0.031
Combined Quebec and Toronto Premenopausal Samples
rs13104269 AA = 1142,
AG/GG = 191
1.181, 1.156 1.171–1.191,
1.137–1.176
0.015 0.956, 0.938 0.947–0.964,
0.921–0.955
0.051
rs2627804 GG = 365,
GA = 662,
AA = 325
1.170, 1.173,
1.195
1.156–1.185,
1.162–1.185,
1.180–1.210
0.021 0.945, 0.949,
0.973
0.932–0.958,
0.938–0.959,
0.960–0.987
0.002
rs2636683 CC = 662,
CT = 549,
TT = 121
1.185, 1.172,
1.163
1.174–1.197,
1.159–1.184,
1.139–1.186
0.080 0.962, 0.945,
0.944
0.951–0.972,
0.934–0.956,
0.923–0.965
0.029
LS BMD, lumbar spine bone mineral density; FN BMD, femoral neck bone mineral density.
a Adjusted means.
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lator of osteoclastogenesis and bone mass in both mouse and
human.
The opposite roles played by the targeted native and phos-
phatase-inactive Inpp4ba in OC differentiation rate and potential
as well as on OC size pointed to the phosphatase catalytic
activity as a critical determinant in this differentiation process.
Interestingly, the reduced OC cell number and size caused by
Inpp4ba overexpression is analogous to the negative effect of
the isoenzyme Inpp4aa on megakaryocytes and fibroblasts
growth (Vyas et al., 2000). Importantly, this analysis provided
the first evidence that Inpp4ba can act as a negative regulator
of osteoclast differentiation. This finding is further supported in
the osteopetrotic gl/gl mice with concomitant Inpp4ba reduced
expression and osteoclast differentiation and number stimula-
tion, most likely as a compensatory response mechanism.
Our data identified NFATc1 as a major downstream target
regulated by Inpp4b to modulate RANKL induced osteoclast
differentiation pathways. Since Ins(1,3,4)P3 a product of IP3
signaling is the preferred substrate of Inpp4b, it could provide
an indirect mechanism by which Inpp4b affect calcium flux
downstream of PLCg activation. Indeed, the reciprocal response
by the native and inactive Inpp4ba, on intracellular calcium
release andNFATc1 nuclear translocation/levels in theOCdiffer-
entiation model further supports that Inpp4ba acts on calcium
signaling to modulate NFATc1 regulatory pathway. The particu-
larly strong constitutive response induced by the phosphatase-
inactive Inpp4ba independently of RANKL activation showed
that Inpp4ba could bypass RANKL to modulate the NFATc1
pathway. Consistent with our results, it has been shown that
introduction of NFATc1 in null NFATc1 bone marrow monocytes
was both essential and sufficient to rescue osteoclastogenesis in
absence of RANKL (Takayanagi et al., 2002). Importantly,
elevated NFATc1 nuclear translocation during Inpp4b/ osteo-474 Cell Metabolism 14, 466–477, October 5, 2011 ª2011 Elsevier Inclast differentiation validated Inpp4b as an in vivo modulator of
NFATc1 signaling pathway. The transcriptional profile of NFATc1
osteoclast-specific genes in mice and in cells converged to indi-
cate that Inpp4ba has a dominant function on NFATc1 signaling
pathway. More precisely, the comparable transcriptional pattern
of target genes for the null Inpp4ba and phosphatase-inactive
Inpp4ba and the opposite pattern for the native Inpp4b assigned
a central function to the Inpp4b phosphatase catalytic activity.
Similar functional impact of the phosphatase-inactive Inpp4ba
and of Inpp4ba-deficiency on osteoclast differentiation indicates
that the phosphatase-inactive mutant is most likely acting as
a dominant negative. Consistently, our results showed that
Inpp4ba phosphatase function is amajor determinant of NFATc1
expression, nuclear localization and transcriptional activation.
These findings suggest that Inpp4ba is a key regulator of the
NFATc1 osteoclastogenesis pathway.
A crucial role of Inpp4ba was determined in vivo in Inpp4b-
deficient mice in which a significant increased in the osteoclast
cell population and bone resorption resulted in a net bone loss
and osteoporosis. Since this phenotype is reminiscent of the
Inositol-5-phosphatase SHIP1 deficient mice (Takeshita et al.,
2002), it could be inferred that the levels of PtdInsP second
messengers modulate osteoclast cell population and normal
osteoclastogenesis. Indeed, loss of SHIP1 promoted increase
mature osteoclast survival, arguing for activation of AKT
signaling by PI(3,4,5)P3 modulation. However, loss of Inpp4b
in OC differentiation and maturation had very little effect on
AKT signaling whereas the downstream PLCg pathway was
activated most likely via IP3 modulation. Our studies highlight
a distinct signaling cascade for the inositol phosphatase Inpp4b
in OC differentiation from SHIP1 mechanism in mature osteo-
clasts. This general physiological mechanism of Inpp4b will be
dissected cellularly in OC and OB lineages in targeted rescue
experiments. Nevertheless together our findings and those ofc.
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phosphatases in osteoclast differentiation and maturation is
critical to maintain normal bone physiology, remodeling and
bone mass.
Importantly, a role for INPP4B was also revealed in human
bone physiology. We identified in our genetic screen a specific
INPP4B SNP significantly associated with BMD variability in
healthy individuals. Our results defined INPP4B as a second
locus that modulates bone mass with a similar impact as LRP5
in human Caucasian populations (Giroux et al., 2007). Similar
to LRP5 set of studies, series of replication in additional cohorts
and functional studies should be undertaken to consolidate
INPP4B as amajor BMD contributor. From a clinical perspective,
INPP4B could become a clinical marker to predict osteopenia or
even osteoporosis in the general women population.
In summary, this study identified Inpp4b as a regulator of os-
teoclatogenesis and bone mass in both mouse and human.
This regulatory mechanism requires Inpp4ba phosphatase cata-
lytic function that controls intracellular calcium and modulates
the NFATc1 signaling pathway. That INPP4B is associated with
BMD variability in human reveals a genetic determinant and
provides a potential therapeutic target and a biomarker for oste-
oclast defects and osteoporosis.
EXPERIMENTAL PROCEDURES
Mice
The mouse strains GL/Le dl+/+gl backcrossed for 120 generations and c-
src+/ were obtained from The Jackson Laboratory (Bar Harbor, ME). Animal
use complied with the guidelines of the Canadian Committee for Animal
Protection and was approved by the local institutional animal care committee.
Generation of Inpp4b/ mice was specifically designed to generate a similar
mutation to the spontaneous weeblemutation in Inpp4a (Nystuen et al., 2001)
(Supplemental Experimental Procedures and Figure S4).
PCR-Based Differential Display Screening
PCR-based differential screening was conducted as described (Liang et al.,
1993). Long bones (femurs and tibia) were dissected from control, gl/gl and
oc/oc mice cleaned from soft tissues and frozen in liquid nitrogen. Bones
were grinded into powder with mortar/pestle kept on dry ice and RNA ex-
tracted with Trizol reagent (Invitrogen, Burlington, Canada). Total bone RNA
(0.5 mg) was annealed with individual T12NC, T12NG or T12NA (N = A, T, C,
or G) primer and reverse transcribed. Radiolabeled PCR amplification was
then carried out with one of the arbitrary 16 to 20 primers and either T12MC,
T12MG, or T12MA primer, 1 ml dATP a35S (1200 Ci/mmol), and 1.5 U Taq poly-
merase. Amplified complementary DNAs (cDNAs) were separated on 6%
sequencing gel and bands were excised from dried gels, reamplified and
sequenced.
Production of Fusion Protein and Transfectants
The mouse full-length Inpp4ba cDNA truncated from the stop codon onward
was amplified and cloned in pEGFP-N1 vector (Clontech, Mountain View,
CA). To abolish phosphatase activity the catalytic cysteine, C845, was mutated
to an alanine resulting in pInpp4ba(C845A)-EGFP construct (Supplemental
Experimental Procedures and Figure S2). RAW 264.7 cell line (TIB-71)
(ATCC, Manassas, VA) were electroporated and several individual stable
clones expressing EGFP, Inpp4ba-EGFP, or Inpp4ba(C845A)-EGFP were
selected with G418 (500 mg/ml). Osteoclasts were generated from each clone
in culture on either plastic or glass in a-MEM medium with 10% FBS and
RANKL (50 ng/ml).
Osteoclast Production
Osteoclasts were generated ex vivo by coculturing of newborn primary
calvaria osteoblasts (Sanjay et al., 2001) and bone marrow or spleen cells ofCelleither wild-type or gl/gl mice (Rajapurohitam et al., 2001). Alternatively, OCs
were obtained by differentiation of individual stable transfectants in the pres-
ence of RANKL (50 ng/ml) or from preosteoclasts obtained after incubation
with M-CSF (10 ng/ml) for 6 days. Multinucleated OCs were identified by
TRAP staining (Collin-Osdoby et al., 2003), and pit resorption assay was per-
formed as described previously (Miyazaki et al., 2004) on dentine or with the
BD BioCoat Osteologic Bone Cell Culture System.
Apoptosis Measurement in RAW 264.7 Cells
RAW 264.7 cells were cultured on nontreated plastic culture dish in presence
or absence of RANKL (50 ng/ml) for 48 hr. Cells were detached with 0.5 mM
EDTA in PBS 13, washed three times with PBS 13, and stained with FITC-
Annexin V and propidium iodine (PI) with a commercially available kit (BD
Biosciences). Stained cell suspensions were next analyzed by FACS. Only
cells positive for Annnexin V but negative for PI were considered as apoptotic.
Gene and Protein Expression Analysis
For kinetics of gene/protein expression, cells were cultured in a-MEMmedium
with 0.5% FBS and then stimulated with 100 ng/ml of RANKL for various times.
Total RNA (500 ng) of OCs and various tissues from 3 week-old wild-type and
gl/gl mice were reverse-transcribed (SuperScriptII transcriptase, Invitrogen,
Burlington, Canada). Semiquantitative PCR expression analysis of the Inpp4b
alpha and beta 30 splicing isoforms used the same Inpp4b forward primer
50-GATTAAAGAAGGCCAGTTGC-30 and two specific reverse Inpp4b primers:
alpha reverse 50-ACTTGGGGAAAGCCATCAGC-30 and beta reverse
50-AGAAGTGTCGAGAAGTTGGC-30. The specific alpha and beta PCR prod-
ucts were 533 bp and 447 bp, respectively. All specific band intensities were
quantified with ImageQuant software. Quantitative PCR was performed on
DNaseI-treated total RNA reverse transcript with polydT primers with Super-
script II first stand cDNA synthesis kit (Invitrogen). The primers used for the
analysis were designed with GeneFisher 2 software and are listed in the
Supplemental Experimental Procedures.
Protein extraction and western analysis were conducted as previously
(Rajapurohitam et al., 2001), with phophospecific antibodies against AKT
(phospho T-308 and phospho S-473), p38, ERK, and JNK (Cell Signaling Tech-
nology), or Inpp4ba polyclonal purified antiserum. These blots were reprobed
with total NFkB p50 (Santa Cruz), NFATc1, b-actin, tubulin, lamin (BD Biosci-
ences), JNK, and AKT antibodies (Cell Signaling Technology).
In Vitro Phosphatase Assays
PI(3,4)P2, PI(3,4,5)P3, PI(4,5)P2, Ins(1,3,4)P3, and Ins(1,4,5)P3 (Echelon
Research Laboratories, NJ) at 50 mM were incubated in phosphatase assay
BF (50 mM MOPS [pH 7.0], 10 mM EDTA) for 1 hr at 30C with Inpp4ba-
EGFP, Inpp4ba(C845A)-EGFP (EGFP-immunoprecipitates from transfected
COS-7 cells), or a control EGFP immunoprecipitate. Free Pi generated was
measured by malachite green assay (R&D System) with a microplate reader
at 620 nm. Data were corrected for background activity by substraction of
phosphatase absorbance from absorbance for each reaction.
Intracellular Calcium Measurement
Transfected cells and pre-osteoclasts were incubated in aMEMwith 10% FBS
and RANKL (50 ng/ml) for 48 hr and 24 hr, respectively. Intracellular calcium
concentration was evaluated in cells loaded with 5 mM fluo-4 AM and 5 mM
Fura Red AM (Invitrogen) for 30 min in serum-free DMEM supplemented
with 0.1% BSA, 10 mM HEPES (pH 7.4), and 50 ng/ml RANKL; cells were
then washed and resuspended in HANK’s salt solution. By confocal micros-
copy, cells were excited at 488 nm and emission signals for fluo-4 (505–
530 nm) and for Fura Red (600–680 nm) were recorded simultaneously at 5 s
intervals. To evaluate the intracellular Ca2+ concentration in single cells, the
ratio of the fluorescence intensity from the fluo-4 to Fura Red was calculated.
As control, the maximum ratio increase was determined by addition of 10 mM
ionomycin at the end of each experiment.
Bone Physiologic Parameters
Bone histology and staining were conducted as described (Rajapurohitam
et al., 2001). Bone parameters were quantified with microCT (SkyScan1072)
technologies. Urine levels of deoxypyridinoline crosslinks were determined
with a commercial kit (Quidel Corporation) and normalized to urine creatinineMetabolism 14, 466–477, October 5, 2011 ª2011 Elsevier Inc. 475
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on bone sections stained with alkaline phosphatase (ALP). Bone histomorph-
ometry was performed as previously (Chappard et al., 1987; Parfitt et al.,
1987). In brief, femur and lumbar vertebrae were dissected, fixed for 24 hr in
10% formalin, dehydrated in graded ethanol series, and embedded in methyl
methacrylate resin according to standard protocols. Von Kossa/Von Gieson
staining was performed on 7 mm sections for bone volume over tissue volume
(BV/TV) measurement. Bone formation rate (BFR) and mineralization apposi-
tion rate (MAR) were analyzed by the calcein double-labeling method (Ducy
et al., 2000a). Calcein (Sigma) was dissolved in buffer (0.15 M NaCl, 2%
NaHCO3) and injected twice at 0.125 mg/g body weight on days 1 and 4,
and mice were sacrificed on day 6. Five-micron bone sections were cleared
in xylene and used for bone formation rate (BFR) measurements. Histomor-
phometric analyses were performed using the Osteomeasure Analysis System
(Osteometrics, Atlanta, GA).
Human Samples and Genotyping
Subjects were recruited from two Canadian metropolitan regions, the Quebec
City metropolitan region for the discovery sample (n = 693) and the Toronto
metropolitan region for the replication sample (n = 660) (Giroux et al., 2008).
All subjects were premenopausal women and provided written, informed
consent, and each institution approved the study through their ethics review
board. We used the HapMap results and Tagger pairwise program (Barrett
et al., 2005; Frazer et al., 2007) to select 83 SNPs. These SNPs were chosen
as tag common genetic variants with a minor allele frequency (MAF) greater
than 5% and a correlation index r2 of 0.8 within the entire coding region of
INPP4B and 40 kb in 50 of the coding region as well as 10 kb in 30, covering
452 kb of genomic DNA of chromosome 4. Genotyping was performed by
the Sequenom iPlex Gold technology (Genome Quebec Innovation Center)
with the DNA from the Quebec sample (n = 693) and two controls samples
from Centre d’Etude du Polymorphisme Humain were genotyped on each
96-well plate of individual DNAs and compared with HapMap results. The
call cluster plot was also evaluated and the Hardy-Weinberg equilibrium was
confirmed. FN BMD and LS BMD were tested separately for association
with each SNP by ANCOVA analysis adjusted for environmental variables
(age, weight, age at menarche, physical activity and smoking). Only three
SNPs had a p value lower than 0.05 with either FN BMD or LS BMD.
Rs13104269 was analyzed in two groups because the GG genotype was too
rare and thus was combined with GA (MAF = 6.9%). The sample from Toronto
(n = 660) was genotyped with these three SNPs with the same technology
and analyzed in combination with the discovery sample as described above
(n = 1353).
Data Analysis
Data are presented as means ± SEM. Statistical analysis was performed by
two-tailed Student’s t test. The value of p < 0.05 was considered as significant.
Simultaneous comparison of groups was performed via ANOVA. The SNP’s
statistical analysis has been described previously (Giroux et al., 2007).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at doi:10.
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